Ionis - IONS Net Assets per Single Share

Graphic logo of Ionis Pharmaceuticals (IONS)

Stable demand for gene therapy renders the Ionis Pharmaceuticals (IONS) business defensive, which, combined with the automation of oligonucleotide synthesis, accelerates preclinical research. The projected book value per share visualizes this potential, where the value 2.64 indicates the current asset magnitude. High margins are sustained through reliable distribution networks that guarantee the secure transport of complex biologics.

Ionis Pharma (IONS) Equity per Share: for the period 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for ionispharma.com (IONS)

- price and consensus price forecast:
Price Chart Ionis Pharma|IONS - Broker Consensus Forecast
- market capitalization data:
Market Value Ionis Pharmaceuticals|IONS - Company Buyout Price
- book capitalization data:
Book Value per Share Ionis|IONS - Accounting Capitalization|Market Value to Book Value Ratio ionispharma.com|IONS - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Ionis Pharmaceuticals|IONS - Long-Term Debt to Capital|Short-Term Debt to Capital Ionis|IONS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Ionis Pharmaceuticals
Fundamental company valuation:Ionis Pharma, IONS
Manufactured products of ionispharma.com

Ionis Pharmaceuticals (IONS) dominates the RNA therapeutics segment thanks to its unique drug development platform. This indicator reflects the company's net assets divided by the number of shares, determining the intrinsic value of the business. By analyzing the book value per share, an investor assesses the actual equity minus liabilities. Growth in this metric confirms the effective capitalization of scientific achievements. Stable dynamics justify the resilience of the asset's market valuation.

Competitor analysis for Ionis Pharmaceuticals

Tempus AI, Inc. (TEM) - Net Assets per Single Share|QGEN: Equity per Share|Repligen Corporation - Net Assets per Single Share|aviditybiosciences.com (RNA) - Net Assets per Share|Book Value per Share CRISPR Therapeutics (CRSP)|Equity per Share WGS|Net Assets per Single Share Ultragenyx Pharma RARE|Equity per Share Beam Tx (BEAM)|Book Value per Share SRPT (Sarepta Therapeutics, Inc.)|Book Value per Share twistbioscience.com TWST|Book Value per Share TXG (10x Genomics)|NTLA: Net Assets per Share|Net Assets per Single Share STOK|BLFS (BioLife) - Net Asset Value per Share|Net Assets per Single Share Wave Life Sciences (WVE)|Equity per Share mazetx.com|SION (Sionna Therapeutics) - Book Value per Share|Net Assets per Share PRME (Prime Medicine Inc)|Net Assets per Single Share TSHA|QURE - Net Assets per Share|Accounting Value per Share MeiraGTx Holdings plc (MGTX)|RGNX: Accounting Value of a Share|Net Assets per Single Share Solid Biosciences (SLDB)|Ocugen Inc (OCGN) - Share Book Value|PACB - Book Value per Share|Accounting Value of a Share Benitec Corp|Book Value per Share DSGN|Book Value per Share RCKT (rocketpharma.com)|Net Assets per Single Share 4D Molecular Therapeutics, Inc.|Lexeo Therapeutics Inc. - Accounting Value of a Share|KRRO: Net Assets per Single Share|EDIT - Accounting Value per Share|SLN: Book Value per Share|ProQR Therapeutics (PRQR) - Book Value per Share|Book Value per Share CDXS|Accounting Value per Share Sangamo Therapeutics Inc.|Nautilus Biotechnology - Book Value per Share|Net Asset Value per Share Metagenomi Therapeutics MGX|Accounting Value per Share DTIL (Precision BioSciences, Inc.)|GBIO - Book Value per Share|Accounting Value per Share Boundless Bio BOLD|XCUR - Book Price of a Share|imunon.com - Book Value per Share|Phio Pharmaceuticals Corp. (PHIO) - Net Assets per Share|Book Value per Share MBIO|Accounting Value per Share TransCode|Book Value per Share BNGO|Book Value per Share APDN (Applied DNA Sciences Inc)|Net Assets per Single Share Bluebird Bio BLUE|ImmunoPrecise Antibodies Ltd - Net Assets per Single Share|Net Assets per Single Share OMGA (Omega Therapeutics)|OMIC - Net Assets per Share|Regulus Therapeutics Inc. - Book Value per Share|SYRS (Syros Pharmaceuticals Inc.) - Net Assets per Share|Net Assets per Single Share TBIO (Codex DNA)|Net Asset Value per Share TCON|Net Assets per Single Share Unity Biotechnology UBX